Key result
Angiotensin II receptor blockers were as effective as other antihypertensive drugs on pulse wave velocity, but superior in improving augmentation index in hypertensive patients without comorbidities.
Why the study?
Do angiotensin II receptor blockers (ARBs) improve pulse wave velocity (PWV) and augmentation index (AIx) more than other antihypertensive drugs in hypertensive patients with no co-morbidities?
Do angiotensin II receptor blockers (ARBs) improve pulse wave velocity (PWV) and augmentation index (AIx) more than other antihypertensive drugs in hypertensive patients with no co-morbidities?
ARBs may offer superior benefits on augmentation index compared to other antihypertensive classes in uncomplicated hypertension, though effects on pulse wave velocity are comparable.
In their meta-analysis Chen and co-authors pooled together ten randomized controlled studies assessing the effect of angiotensin II receptors blockers (ARBs) on pulse wave velocity (PWV) and augmentation index (AIx), compared to a mix of other antihypertensive drugs (1). The authors documented that ARB treatment was as effective as dihydropyridine calcium channel blockers, beta-blockers and diuretics on PWV, whereas the effect on AIx was superior with ARBs. Authors deliberately settled to limit their systematic review to hypertensive patients with no co-morbidities, in order to avoid any external bias on the evaluation of treatment efficacy. They also decided to include in the meta-analysis only studies with a sufficiently long-term follow-up, in order to increase the chance of observing a significant treatment effect.
No takes yet. Share an insight, caveat, or question.
Stefano Omboni (2016) conducted an editorial in Hypertension. Angiotensin II receptor blockers (ARBs) vs. Other antihypertensive drugs (dihydropyridine calcium channel blockers, beta-blockers and diuretics) was evaluated on Pulse wave velocity (PWV) and augmentation index (AIx). Angiotensin II receptor blockers were as effective as other antihypertensive drugs on pulse wave velocity, but superior in improving augmentation index in hypertensive patients without comorbidities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: